Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Castle Biosciences (CSTL) 10K Form and Latest SEC Filings 2026

Castle Biosciences logo
$20.42 +0.40 (+1.97%)
As of 02:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Castle Biosciences SEC Filings & Recent Activity

Castle Biosciences (NASDAQ:CSTL) has submitted 542+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Castle Biosciences's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026.

Form 4
CASTLE BIOSCIENCES INC Reports Ownership Change on Apr. 23, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Castle Biosciences Files Quarterly Report on Nov. 3, 2025

The 10-Q contains Castle Biosciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Castle Biosciences SEC Filing History

Browse Castle Biosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 7:10 AM
Castle Biosciences (1447362) Subject
RTW INVESTMENTS, LP (1493215) Filed by
Form SCHEDULE 13G/A
05/07/2026 3:56 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/23/2026 3:16 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 3:34 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 9:13 AM
Castle Biosciences (1447362) Filer
Form DEF 14A
04/08/2026 9:13 AM
Castle Biosciences (1447362) Filer
Form DEFA14A
04/08/2026 9:14 AM
Castle Biosciences (1447362) Filer
Form ARS
03/30/2026 5:27 PM
Castle Biosciences (1447362) Issuer
Cotton Rodney (2015732) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/30/2026 5:29 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 4:36 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/26/2026 3:42 PM
Castle Biosciences (1447362) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/16/2026 3:07 PM
Castle Biosciences (1447362) Issuer
Juvenal Tobin W (1856542) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 3:52 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/09/2026 3:12 PM
Castle Biosciences (1447362) Issuer
Cole G Bradley (1337798) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 3:13 PM
Castle Biosciences (1447362) Issuer
Stokes Frank (1782815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 4:08 PM
Castle Biosciences (1447362) Issuer
Stokes Frank (1782815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 4:12 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 4:16 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 4:18 PM
Castle Biosciences (1447362) Issuer
Juvenal Tobin W (1856542) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 3:28 PM
Castle Biosciences (1447362) Subject
Stokes Frank (1782815) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/26/2026 3:13 PM
Castle Biosciences (1447362) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/17/2026 7:31 AM
Castle Biosciences (1447362) Subject
RTW INVESTMENTS, LP (1493215) Filed by
Form SCHEDULE 13G
02/05/2026 3:17 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 3:15 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 12:21 PM
Castle Biosciences (1447362) Subject
DIMENSIONAL FUND ADVISORS LP (354204) Filed by
Form SCHEDULE 13G/A
01/14/2026 3:30 PM
Castle Biosciences (1447362) Issuer
Stokes Frank (1782815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 3:30 PM
Castle Biosciences (1447362) Issuer
Juvenal Tobin W (1856542) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 3:30 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 3:30 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 8:43 AM
Castle Biosciences (1447362) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 3:06 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:06 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:06 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 3:49 PM
Castle Biosciences (1447362) Subject
Oelschlager Kristen M (1856565) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/17/2025 3:20 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 5:21 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/15/2025 3:08 PM
Castle Biosciences (1447362) Issuer
Stokes Frank (1782815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 3:09 PM
Castle Biosciences (1447362) Issuer
Juvenal Tobin W (1856542) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 5:44 PM
Castle Biosciences (1447362) Issuer
Juvenal Tobin W (1856542) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 5:46 PM
Castle Biosciences (1447362) Issuer
Stokes Frank (1782815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 5:47 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
The REAL Reason Trump is Invading Iran (Ad)

For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel

Click here to find out what it is.
12/11/2025 5:48 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 3:30 PM
Castle Biosciences (1447362) Subject
Juvenal Tobin W (1856542) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/08/2025 3:28 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2025 3:08 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 1:58 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2025 4:11 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/24/2025 3:28 PM
Castle Biosciences (1447362) Subject
Juvenal Tobin W (1856542) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/24/2025 3:24 PM
Castle Biosciences (1447362) Issuer
Juvenal Tobin W (1856542) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 3:07 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 5:58 AM
Castle Biosciences (1447362) Subject
Stokes Frank (1782815) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2025 6:03 AM
Castle Biosciences (1447362) Subject
Juvenal Tobin W (1856542) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/04/2025 7:56 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2025 7:38 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4/A
11/03/2025 3:16 PM
Castle Biosciences (1447362) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/03/2025 3:20 PM
Castle Biosciences (1447362) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
10/23/2025 8:30 AM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/09/2025 12:48 PM
Castle Biosciences (1447362) Subject
DIMENSIONAL FUND ADVISORS LP (354204) Filed by
Form SCHEDULE 13G
10/06/2025 3:11 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 4:17 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/19/2025 3:05 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 3:04 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:04 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:04 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2025 5:15 PM
Castle Biosciences (1447362) Subject
Oelschlager Kristen M (1856565) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/27/2025 3:56 PM
Castle Biosciences (1447362) Subject
Oelschlager Kristen M (1856565) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2025 4:19 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2025 4:30 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/12/2025 3:30 PM
Castle Biosciences (1447362) Issuer
Juvenal Tobin W (1856542) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2025 3:31 PM
Castle Biosciences (1447362) Issuer
Oelschlager Kristen M (1856565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2025 3:31 PM
Castle Biosciences (1447362) Issuer
Stokes Frank (1782815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2025 3:32 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025 3:05 PM
Castle Biosciences (1447362) Issuer
MAETZOLD DEREK J (1239501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 5:11 PM
Castle Biosciences (1447362) Subject
MAETZOLD DEREK J (1239501) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/23/2025 4:01 PM
Castle Biosciences (1447362) Issuer
Cole G Bradley (1337798) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:39 PM
Castle Biosciences (1447362) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Castle Biosciences SEC Filings - Frequently Asked Questions

Castle Biosciences (CSTL) has submitted 542+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Castle Biosciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Castle Biosciences's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:CSTL) was last updated on 5/21/2026 by MarketBeat.com Staff.
From Our Partners